毛发上皮瘤
基底细胞癌
恶性肿瘤
病理
雄激素受体
肿瘤
基础(医学)
染色
生物
免疫组织化学
医学
癌
内科学
癌症
基底细胞
胰岛素
前列腺癌
作者
Osward Y. Carrasquillo,Estefanía Cruzval-O’Reilly,Julio E. Sánchez,Sheila M. Valentín‐Nogueras
出处
期刊:American Journal of Dermatopathology
[Ovid Technologies (Wolters Kluwer)]
日期:2020-08-17
卷期号:43 (3): 191-197
被引量:5
标识
DOI:10.1097/dad.0000000000001783
摘要
Abstract: Basal cell carcinoma (BCC) is the most common malignancy of the skin. It is an epithelial neoplasm with origin in the precursor cells of the interfollicular epidermis. Even though it has low metastatic potential, delay in management may lead to local destruction and morbidity. In contrast, trichoepithelioma (TE) is a benign tumor originating from the outer root sheath of the hair follicle. Similar to BCC, TE tends to affect the head and neck region. Both neoplasms may exhibit clinical and histopathological similarities, making them prone to misdiagnosis. Multiple immunomarkers have been used to distinguish among these entities, but so far, no single agent or combination of agents appear to be neither sensitive nor specific enough to differentiate between them. This study was divided into 2 parts. First, 17 cases of BCC and 14 cases of TE were stained with androgen receptor and bcl-2. Then, 27 cases of borderline/equivocal of BCC and 13 cases of borderline/equivocal TE were stained with the same protocol. Sensitivity and specificity were calculated for each individual immunomarker and for the combination of them. Androgen receptor positivity was 100% specific for BCC and borderline/equivocal BCC, whereas bcl-2 diffuse staining pattern demonstrated a sensitivity of 82.4% for BCC and 88.9% borderline/equivocal BCC. When both immunomarkers were combined, the sensitivity for BCC decreased (70.6%) but the specificity remained high (100%). Similarly, the sensitivity for borderline/equivocal BCC was 55.6%, whereas the specificity was 100%. Although moderately sensitive, combining both immunomarkers showed an excellent specificity to discriminate between BCC and TE.
科研通智能强力驱动
Strongly Powered by AbleSci AI